[HTML][HTML] Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

SA Jones, J Scheller… - The Journal of clinical …, 2011 - Am Soc Clin Investig
SA Jones, J Scheller, S Rose-John
The Journal of clinical investigation, 2011Am Soc Clin Investig
The successful treatment of certain autoimmune conditions with the humanized anti–IL-6
receptor (IL-6R) antibody tocilizumab has emphasized the clinical importance of cytokines
that signal through the β-receptor subunit glycoprotein 130 (gp130). In this Review, we
explore how gp130 signaling controls disease progression and examine why IL-6 has a
special role among these cytokines as an inflammatory regulator. Attention will be given to
the role of the soluble IL-6R, and we will provide a perspective into the clinical blockade of IL …
The successful treatment of certain autoimmune conditions with the humanized anti–IL-6 receptor (IL-6R) antibody tocilizumab has emphasized the clinical importance of cytokines that signal through the β-receptor subunit glycoprotein 130 (gp130). In this Review, we explore how gp130 signaling controls disease progression and examine why IL-6 has a special role among these cytokines as an inflammatory regulator. Attention will be given to the role of the soluble IL-6R, and we will provide a perspective into the clinical blockade of IL-6 activity in autoimmunity, inflammation, and cancer.
The Journal of Clinical Investigation